EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry

Johan Gobom, Ann Brinkmalm, Gunnar Brinkmalm, Kaj Blennow, Henrik Zetterberg

Molecular & Cellular Proteomics · 2024-02 · 23 (2) · 100721

DOI: 10.1016/j.mcpro.2024.100721 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular & Cellular Proteomics, 2024-02. Verfasst von Johan Gobom und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölnd…. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alzheimerfonden, EU Joint Programme – Neurodegenerative Disease Research, UK Dementia Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is characterized by several neuropathological changes, mainly extracellular amyloid aggregates (plaques), intraneuronal inclusions of phosphorylated tau (tangles), as well as neuronal and synaptic degeneration, accompanied by tissue reactions to these processes (astrocytosis and microglial activation) that precede neuronal network disturbances in the symptomatic phase of the disease. A number of biomarkers for these brain tissue changes have been developed, mainly using immunoassays. In this review, we discuss how targeted mass spectrometry (TMS) can be used to validate and further characterize classes of biomarkers reflecting different AD pathologies, such as tau- and amyloid-beta pathologies, synaptic dysfunction, lysosomal dysregulation, and axonal damage, and the prospect of using TMS to measure these proteins in clinical research and diagnosis. TMS advantages and disadvantages in relation to immunoassays are discussed, and complementary aspects of the technologies are discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumanstau ProteinsBrainAmyloid beta-PeptidesBiomarkers

Stichwörter der Autor:innen

Alzheimer's diseaseamyloidbiomarkerstargeted mass spectrometrytau

Substanzen

tau ProteinsAmyloid beta-PeptidesBiomarkers

Autor:innen und Institutionen

  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University…
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.

Förderung

  • Alzheimerfonden
  • EU Joint Programme – Neurodegenerative Disease Research
  • UK Dementia Research Institute
  • Horizon 2020 Framework Programme
  • Olav Thon Stiftelsen
  • Cure Alzheimer's Fund
  • Familjen Erling-Perssons Stiftelse
  • Center for Modelling and Simulation in the Biosciences

Zitieren

APA

Gobom, J., Brinkmalm, A., Brinkmalm, G., Blennow, K., & Zetterberg, H. (2024). Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry. Molecular & Cellular Proteomics, 23(2), 100721. https://doi.org/10.1016/j.mcpro.2024.100721

Vancouver

Gobom J, Brinkmalm A, Brinkmalm G, Blennow K, Zetterberg H. Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry. Molecular & Cellular Proteomics. 2024;23(2):100721. doi:10.1016/j.mcpro.2024.100721

BibTeX
@article{Gobom2024,
  author = {Gobom, Johan and Brinkmalm, Ann and Brinkmalm, Gunnar and Blennow, Kaj and Zetterberg, Henrik},
  title = {Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry},
  journal = {Molecular & Cellular Proteomics},
  year = {2024},
  volume = {23},
  number = {2},
  pages = {100721},
  doi = {10.1016/j.mcpro.2024.100721}
}
Kostenlos starten →